# A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)

> **NCT00830076** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 18 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** sitagliptin phosphate
- **DRUG:** metformin hydrochloride
- **DRUG:** Comparator: placebo sitagliptin
- **DRUG:** Comparator: placebo metformin

## Key facts

- **NCT ID:** NCT00830076
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-02
- **Primary completion:** 2009-04-30
- **Final completion:** 2009-05-14
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00830076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00830076, "A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00830076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*